Data from Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib

Abstract

<div>Abstract<p><b>Purpose:</b> EphA2 is an attractive therapeutic target because of its diverse roles in cancer growth and progression. Dasatinib is a multikinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are needed.</p><p><b>Experimental design:</b> The effects of dasatinib on human uterine cancer cell lines were examined using a series of <i>in vitro</i> experiments, including MTT, Western blot analysis, and plasmid transfection. <i>In vivo</i>, an orthotopic mouse model of uterine cancer was utilized to identify the biologic effects of dasatinib. Molecular markers for response prediction and the mechanisms relevant to response to dasatinib were identified by using reverse phase protein array (RPPA), immunoprecipitation, and double immunofluorescence staining.</p><p><b>Results:</b> We show that high levels of CAV-1, EphA2 phosphorylation at S897, and the status of PTEN are key determinants of dasatinib response in uterine carcinoma. A set of markers essential for dasatinib response was also identified and includes CRaf, pCRaf<sup>S338</sup>, pMAPK<sup>T202/Y204</sup> (mitogen-activated protein kinase [MAPK] pathway), pS6<sup>S240/244</sup>, p70S6k<sup>T389</sup> (mTOR pathway), and pAKT<sup>S473</sup>. A novel mechanism for response was discovered whereby high expression level of CAV-1 at the plasma membrane disrupts the BRaf/CRaf heterodimer and thus inhibits the activation of MAPK pathway during dasatinib treatment.</p><p><b>Conclusions:</b> Our <i>in vitro</i> and <i>in vivo</i> results provide a new understanding of EphA2 targeting by dasatinib and identify key predictors of therapeutic response. These findings have implications for ongoing dasatinib-based clinical trials. <i>Clin Cancer Res; 20(7); 1846–55. ©2014 AACR</i>.</p></div>